Frequently Asked Questions

We offer individual tests and bundled panels across chemical, biological, and method suitability categories. Chemical tests include basic HPLC purity ($160), expanded purity with mass spec ID and aggregate analysis ($200), potency and total peptide mass ($200), heavy metals by ICP-MS ($200), and volatile organic compounds including TFA and acetate ($200 each). Biological tests include endotoxin by LAL assay ($200), sterility by USP 71 ($175) or rapid Celsis method ($250), and antimicrobial effectiveness ($500). Bundled panels: Basic Research QC — purity plus potency ($350); Standard QC — expanded purity, potency, and heavy metals ($600); Full Injectable Panel — expanded purity, potency, heavy metals, endotoxins, and rapid sterility ($1,050). Method suitability studies are available separately for sterility ($1,800), endotoxin ($675), and potency ($1,200).

We test all research and compounded peptides. GLP-1 compounds including semaglutide, tirzepatide, and retatrutide. Research peptides including BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, and custom synthesized sequences. Any peptide intended for compounding or injectable use. If you have a specific compound or formulation that is not on this list, contact us before submitting — method confirmation for unusual sequences or novel analogs may add lead time.

Basic purity ($160) provides chromatographic separation by reverse-phase HPLC with UV detection at 220nm, returning total purity as a percentage against the main peptide peak. Expanded purity ($200) adds mass spectrometry identity confirmation by ESI-MS or LC-MS, total impurity profiling, largest single impurity identification, and aggregate analysis. For injectable applications or supplier qualification, expanded purity is the appropriate choice — it confirms you have the right compound at the stated purity, not just that a primary peak exists. The expanded panel is also the basis for the bundled Standard QC and Full Injectable panels.

Yes. USP 71 sterility and USP 85 endotoxin testing require method suitability to be established for each specific formulation before results are analytically valid. Method suitability demonstrates that the test system performs as expected with your specific compound — that the formulation does not interfere with microbial recovery in sterility testing, or with the LAL reaction in endotoxin testing. Without method suitability on file, a passing sterility or endotoxin result cannot be defended under regulatory audit. We offer sterility method suitability ($1,800), endotoxin method suitability ($675), and potency method suitability ($1,200) as standalone services that run prior to or concurrent with sample testing.

Contact us first to confirm your panel selection and receive packaging and shipping instructions. Most panels require 10–50mg of lyophilized peptide or liquid formulation depending on the tests ordered. We accept overnight shipments from anywhere in the United States. A chain of custody form accompanies every submission — we provide this form before you ship, and it must be included with the sample. Samples received without chain of custody documentation will be held pending contact with the submitting party.

Standard chemical panels — HPLC purity, LC-MS identity, potency, heavy metals, VOCs — return in 5–11 business days from sample receipt. Endotoxin by LAL assay returns within the same window. Rapid sterility via Celsis returns in 5–7 business days. Standard sterility by USP 71 requires a 14-day incubation hold before results can be released — this is a regulatory requirement of the method, not a processing delay. Method suitability studies add lead time; contact us for current turnaround when ordering suitability concurrent with a sample panel. Rush turnaround is available on most chemical tests.

Every COA includes: the test methodology for each analytical method run, raw instrument data and chromatograms for applicable tests, result values with pass/fail determination against stated specifications, analyst certification and signature, and complete chain of custody documentation from sample receipt through sign-off. COAs are delivered electronically and archived in the client portal. Expanded panels include full chromatograms. White-label COA reporting — results delivered under your clinic or pharmacy brand — is available on request.

Yes. We regularly process multi-lot submissions for supplier comparison, batch series for compounding pharmacy release programs, and vendor scorecard engagements where multiple suppliers' products are tested against the same panel simultaneously. Contact us before shipping multi-lot submissions so we can coordinate chain of custody and structure the resulting COAs for direct comparison. Lot history services are also available for research vendors managing COA documentation across multiple buyer relationships.

The minimum for meaningful supplier verification is expanded purity plus potency ($400) — this confirms identity by mass spec, purity by HPLC, and dose accuracy by potency assay. If your program uses injectable formulations, adding heavy metals ($200) and endotoxin ($200) is appropriate, and the Full Injectable Panel at $1,050 covers all of these plus rapid sterility. If you are qualifying multiple suppliers simultaneously, we can process all lots under a single submission with comparative COA documentation. White-label reporting is available if you need results delivered under your clinic brand.

For injectable peptide batch release, the standard panel is expanded purity, potency, endotoxin, and sterility — typically the Full Injectable Panel at $1,050. If method suitability is not already established for your formulations, it must be run before sterility and endotoxin results are analytically defensible: sterility method suitability ($1,800) and endotoxin method suitability ($675). We can run suitability studies concurrent with your first batch submission to compress the timeline. Celsis rapid sterility at 5–7 days versus the 14-day USP 71 hold is a meaningful operational advantage for pharmacies managing release schedules.

Buyers requesting independent COAs are specifically asking for documentation that the seller did not produce. The minimum that satisfies this requirement is expanded purity plus LC-MS identity confirmation — this demonstrates that the compound is what is claimed at the stated purity, from a named independent laboratory. Adding heavy metals and endotoxin to the panel strengthens the document for buyers in clinical or pharmaceutical contexts. We offer vendor scorecard and lot history services for suppliers managing COA documentation across multiple batches and buyer relationships — contact us to discuss the structure.